Solvonis Therapeutics plc
Research Solvonis Therapeutics plc (SVNS) on Bullrun: market cap GBX 10.21M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSVNS
- ExchangeLSE
- CountryUnited Kingdom
- SectorIndustrials
- IndustrySpecialty Industrial Machinery
- CurrencyGBX
- Market capGBX 10.21M
- Financial periodQ4 2024
- RevenueGBP 0
- Net income-GBP 335.00K
- Free cash flow-GBP 149.00K
Valuation Snapshot
latest market cap is GBX 10.21M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | GBX 10.21M | n/a | n/a | n/a |
About Solvonis Therapeutics plc
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder;
Related stock research
Other Industrials stocks
Frequently asked questions
What is Solvonis Therapeutics plc's market cap?
Solvonis Therapeutics plc's market capitalization is GBX 10.21M.
What does Solvonis Therapeutics plc do?
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder; and SVN-015 for the treatment of stimulant use disorder.